| Nasdaq: PCYC
Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The company has three product candidates in clinical development and several preclinical molecules in lead optimization. Its clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. Pharmacyclics was founded on April 19, 1991 and is headquartered in Sunnyvale, CA.